The role of bevacizumab in breast cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 14, 2008, Pages 26-29

  Daniele, Gennaro ^a   Marciano, Roberta ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer

Indexed keywords

AROMATASE INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; INTERLEUKIN 8; LETROZOLE; PACLITAXEL; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 55649116635     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2008.06.006     Document Type: Article

References (35)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
2. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 1 (1997) 4-25
3. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 5 (2005) 1011-1027
4. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 10 (2003) 721-732
5. Kerbel L., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 10 (2002) 727-739
6. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 5 (2006) 549-560
7. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 10 (1995) 1024-1028
8. Netti P.A., Hamberg L.M., Babich J.W., et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 96 6 (1999) 3137-3142
9. Benjamin L.E., Golijanin D., Itin A., et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 2 (1999) 159-165
10. McLeskey S.W., Tobias C.A., Vezza P.R., Filie A.C., Kern F.G., and Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 153 6 (1998) 1993-2006
11. Linderholm B., Grankvist K., Wilking N., Johansson M., Tavelin B., and Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18 7 (2000) 1423-1431
12. Gown A., Rivskin S.E., Hunt H.N., et al. Prognostic factor of vascular endothelial growth factor (VEGF) expression in node-positive breast cancer. Proc Am Soc Clin Oncol 20 (2001) [abstract 1703]
13. Foekens J.A., Peters H.A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61 14 (2001) 5407-5414
14. Gasparini G., Toi M., Gion M., et al. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl. 1 (2000) S37-S44
15. Finkenzeller G., Weindel K., Zimmermann W., Westin G., and Marmé D. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis 7 1 (2004) 59-68
16. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 5 (2004) 1706-1716
17. Linderholm B., Andersson J., Lindh B., et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 40 1 (2004) 33-42
18. Huh J.I., Calvo A., Stafford J., et al. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24 (2005) 790-800
19. Dales J., Garcia S., Bonnier P., et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 23 (2003) 297-305
20. Scott L.J. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 67 12 (2007) 1793-1799
21. Borgström P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19 5B (1999) 4203-4214
22. Borgström P., Hillan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56 17 (1996) 4032-4039
23. Epstein M., Ayala R.E., Tchekmedyian N., Borgstrom P., Pegram D.J., and Slamon D.J. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 76 Suppl. 1 (2002) S143 [abstract 570]
24. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 5 Suppl. 16 (2003) 117-124 October
25. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
26. Miller K.D., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 26 (2007) 2666-2676
27. Ramaswamy B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12 10 (2006) 3124-3129
28. Burstein H.J., Parker L.M., Savoie J., et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbinefor refractory advanced breast cancer. Breast Cancer Res Treat 76 Suppl. 1 (2002) S115 [abstract 446]
29. Burstein H.J., Spigel D.R., Kindsvogel K., et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 94 Suppl. 1 (2005) S6 [abstract 4]
30. Traina T.A., Rugo H., Caravelli J., et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 24 Suppl. 18 (2006) 133S [abstract 3050]
31. Pegram M., Yeon C., Durna L.N., et al. Phase 1 combined biologic therapy of breast cancer using 2 humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor. Breast Cancer Res Treat 88 Suppl. 1 (2004) S124 [abstract 3039]
32. Pegram M., Chan D., Dichmann R.A., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100 Suppl. 1 (2006) S28 [abstract 301]
33. Hyder S.M., Nawaz Z., Chiappetta C., and Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60 12 (2000) 3183-3190 June 15
34. Takei H., Lee E.S., and Jordan V.C. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9 1 (2002) 39-42
35. Nakamura J., Savinov A., Lu Q., and Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137 12 (1996) 5589-5596